Related Experiment Video

Updated: Aug 30, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for

Igor Astsaturov1, Teresa Petrella, E Umit Bagriacik

  • 1Division of Molecular and Cellular Biology, Research Institute, Sunnybrook and Women's College Health Sciences Center, Toronto, Ontario, Canada.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 14, 2003
PubMed
Abstract

Insights

High-dose interferon-alpha (IFN-alpha) therapy can reawaken tumor-specific T cells in melanoma patients previously vaccinated against gp100. This recall of cytotoxic T cells led to tumor regression in some patients, suggesting a method to enhance cancer vaccine efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Vaccinology

Background:

  • Cancer vaccines targeting self-antigens like gp100 may be limited by immune tolerance mechanisms.
  • Recombinant viral vaccines expressing gp100 in melanoma patients induced only transient T cell responses.
  • Interferon-alpha2b (IFN-alpha) was investigated to enhance therapeutic effects of cancer vaccines.

Purpose of the Study:

  • To determine if high-dose IFN-alpha could improve the therapeutic effectiveness of cancer vaccines.
  • To assess the impact of IFN-alpha on T cells specific for tumor antigens (gp100).
  • To evaluate clinical responses and toxicity in melanoma patients receiving IFN-alpha post-vaccination.

Main Methods:

  • Seven HLA-A*0201(+) melanoma patients received high-dose IFN-alpha (20 MU/m(2) x 20 doses) after vaccination.
  • Clinical toxicity and responses were monitored.
  • Effects on gp100-reactive T cells were assessed using IFN-gamma ELISpot, tetramer staining, and cytotoxicity assays.

Main Results:

  • High-dose IFN-alpha recalled gp100-reactive T cells in patients who previously responded to vaccination.
  • These recalled T cells demonstrated in vitro ability to kill gp100-expressing tumor cells.
  • Tumor regression was observed in two patients with metastatic disease, concurrent with T cell reappearance.

Conclusions:

  • High-dose IFN-alpha can effectively recall previously activated tumor-reactive T cells with potent cytotoxic activity.
  • This finding suggests a potential strategy for maintaining and enhancing antitumor immune responses initiated by cancer vaccines.
  • IFN-alpha may overcome tolerance mechanisms limiting cancer vaccine efficacy.

More Related Videos

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model07:05

In Vivo Assay for Detection of Antigen-specific T-cell Cytolytic Function Using a Vaccination Model

Published on: November 28, 2017

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...